Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT02928965 Completed - Clinical trials for Schizophrenia and Disorders With Psychotic Features

The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms

BeneMin
Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.

NCT ID: NCT02928159 Completed - Mood Disorders Clinical Trials

Low Pulse Amplitude Seizure Therapy (LAP-ST Study)

Start date: April 2013
Phase: Phase 1
Study type: Interventional

This study assesses the feasibility of a full course of Low Pulse Amplitude-Seizure Therapy (LAP-ST) (primary outcome).

NCT ID: NCT02921243 Completed - Schizophrenia Clinical Trials

Schizophrenia and the Gut Microbiome

Start date: October 1, 2016
Phase:
Study type: Observational

In a sample of 20 inpatients with a DSM-IV-TR/DSM 5 diagnosis of schizophrenia or schizoaffective disorder, investigators propose to conduct a prospective, 2 week observational trial to collect gastrointestinal stool samples in order to characterize the microbiota in people with schizophrenia and examine its variability over time. Participants may elect to participate for an additional two weeks, during which they will receive the prebiotic, oligofructose-enriched inulin (FOS), in order to examine its effects on the relative preponderance of butyrate-producing bacteria in the gut microbiome. Investigators will use an inpatient sample in order to standardize meals, exercise and environmental mediators. This is considered a feasibility, pilot study in order to apply for future grant funding. Investigators will recruit patients from the Treatment Research Program inpatient unit, Maryland Psychiatric Research Center, University of Maryland School of Medicine.

NCT ID: NCT02918825 Completed - Schizophrenia Clinical Trials

Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

A randomized trial of olanzapine and Long-acting paliperidone palmitate injection in the treatment of 100 treatment- naive first-episode patients with schizophrenia.

NCT ID: NCT02918630 Completed - Tobacco Smoking Clinical Trials

E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia

Start date: October 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to assess if access to an electronic nicotine delivery device, or e-cigarette, in addition to nicotine patch (21 mg) can help reduce cigarette smoking among individuals diagnosed with schizophrenia compared to nicotine patch alone.

NCT ID: NCT02911519 Completed - Schizophrenia Clinical Trials

Brief Group Psychoeducation for Schizophrenia

Start date: August 1, 2013
Phase: N/A
Study type: Interventional

This study evaluates the addition of psychoeducation to treatment as usual in the treatment of adults with schizophrenia for relapse prevention. Half of participants will receive a brief (5 sessions) psychoeducation intervention and treatment as usual in combination, while the other half will receive treatment as usual only.

NCT ID: NCT02906553 Completed - Schizophrenia Clinical Trials

The Role of Nitric Oxide in Cognition in Schizophrenia

NOC
Start date: September 2016
Phase: N/A
Study type: Interventional

This study evaluates the role of the Nitric Oxide system in cognition in patients with schizophrenia. Participants will be randomised to 2 equal groups and receive either the Nitric Oxide donor molecule glyceryl trinitrate, or a placebo. Performance on several cognitive tasks will be assessed.

NCT ID: NCT02905604 Completed - Depression Clinical Trials

Magnetic Stimulation of the Brain in Schizophrenia or Depression

MA-SCH-DEP
Start date: September 29, 2016
Phase: N/A
Study type: Interventional

The primary objective is to evaluate if repetitive transcranial magnetic stimulation (rTMS) with theta burst frequency over dorsomedial prefrontal cortex (DMPFC) is an effective treatment for negative symptoms (anhedonia and avolition) in schizophrenia or depression. Other objectives are to increase the understanding of the underlying neurobiology of negative symptoms and the mechanisms for the treatment effect of rTMS.

NCT ID: NCT02901587 Completed - Schizophrenia Clinical Trials

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Start date: September 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the effect of Lu AF35700 on electrical activity in the heart as measured on an electrocardiogram (ECG) in patients with schizophrenia or schizoaffective disorder after 6 weeks of treatment

NCT ID: NCT02901015 Completed - Schizophrenia Clinical Trials

Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning

EVACO
Start date: April 2013
Phase: N/A
Study type: Interventional

Interventional, multicenter, and longitudinal study, of a cohort of patients with schizophrenia, evaluated on social cognition, neurocognition, symptoms, functioning with 12 months interval.